Authors

Harry Erba, MD, PhD, University of Alabama

Harry Erba, MD, PhD, University of Alabama at Birmingham

Harry H. Yoon, MD

Latest:

A Look Towards the Future of ESCC

Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.

Harry P. Erba, MD, PhD, Duke University School of Medicine

Latest:

The Role of Venetoclax for Treatment of AML

Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.

Harry P. Erba, MD, PhD, Duke University

Harry P. Erba, MD, PhD, UAB

Harry P. Erba, MD, PhD, University of Alabama

Harsha Ranganath, MD

Latest:

Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate Cancer

Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.

Harvard Medical School

Harvey I. Pass, MD

Latest:

Dr. Harvey I. Pass on Personalized Surgical Approaches in Lung Cancer

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.

Hashem El-Serag, MD, MPH

Latest:

Dr. Hashem El-Serag on the Relationship Between NASH and HCC

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Hassane M. Zarour, MD

Latest:

Dr. Zarour on Unmet Needs in Melanoma

Hassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.

Hatem Soliman, MD

Latest:

Dr. Soliman the Utility of ADCs in Breast Cancer

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

Hatem Soliman, MD, H. Lee Moffitt Cancer Center & Research Institute

Hatim Husain, MD

Latest:

Looking Ahead in NSCLC Oncodrivers and Targeted Therapies

Panelists discuss how ASCO 2025 highlighted exciting advances in targeted therapy including neoadjuvant approaches, dynamic biomarkers like circulating tumor DNA, mixed results with HER3-directed antibody-drug conjugates (ADCs) in the EGFR space, but promising data with trastuzumab-based ADCs, emphasizing the critical importance of comprehensive biomarker testing to ensure no patients miss potentially life-changing targeted therapies.

Haydia Haniff

Latest:

Patients Coping With Insomnia May Benefit from Behavioral Interventions

Cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based stress reduction (MBSR) can improve sleep for patients with cancer, but CBT-I continues to be the best nonpharmacologic option

Hayley Virgil

Senior Editor,

Latest:

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Haythem Y. Ali, MD

Latest:

Dr. Ali on the Need to Understand Real-World Disparities in BRCA Testing in TNBC

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

He James Zhu, MD, PhD

Latest:

Dr. Zhu on Mitigating Toxicities of Elective Nodal Irradiation in Breast Cancer

He James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.

Hearn Jay Cho, MD, PhD

Latest:

Dr. Cho on Investigational BiTE Therapies in Multiple Myeloma

Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.